LEXINGTON, Massachusetts — Valo Health has appointed Rita Kale as Chief Financial Officer, bringing more than 20 years of global finance leadership to the company as it accelerates its AI-driven approach to drug discovery and development.
“We are proud to welcome Rita Kale as Valo’s Chief Financial Officer during such a pivotal time at Valo,” said Brian Alexander, MD, MPH, CEO of Valo Health. “Rita’s deep financial expertise and proven track record of strategically scaling organizations make her an invaluable addition to our leadership team. Her ability to align financial strategy with scientific innovation will be instrumental as we accelerate our mission to transform drug discovery and deliver meaningful impact to patients in the future.”
Kale previously served as CFO and Head of Corporate Management at Foundation Medicine, where she played a major role in product expansion and operational improvement initiatives. Earlier in her career, she held senior finance positions within the Roche Group across Asia-Pacific and Sub-Saharan Africa, served as country CFO in South Africa and India, and led finance for Global Product Strategy in Switzerland. Across these roles, she oversaw strategic capital allocation, supported product launches, and helped scale operations in complex healthcare markets. She also serves on the board of CareMetx, a patient access services company.
“I’m thrilled to join Valo at such a transformative time for the company,” said Rita Kale. “Valo’s vision, platform, and team are outstanding. I look forward to combining corporate strategy and operational execution to help accelerate our mission.”
Valo Health uses AI-enabled human causal biology and predictive chemistry to transform early-stage drug discovery. The company advances its own pipeline of therapeutic candidates and collaborates with pharmaceutical partners through a fractional portfolio model that integrates its early research capabilities with large-scale clinical development. Valo aims to deliver new medicines to patients more efficiently by uniting data-driven discovery with industry expertise.
